Impact of proactive low-molecular weight heparin therapy on outcomes in COVID-1 | Zendy

Selçuk Görmez | Zendy; Hilal Kurtoğlu | Zendy; Erkan Ekicibaşi | Zendy; Aleks Değirmencioğlu | Zendy; Atmika Paudel | Zendy; Gökçe Akan | Zendy; Fatmahan Atalar | Zendy; Refik Erdim | Zendy; Emre Eroğlu | Zendy; Selçuk Dağdelen | Zendy; Nevin Sarıgüzel | Zendy; Ceyda Kirisoglu | Zendy; Burak Pamukçu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of proactive low-molecular weight heparin therapy on outcomes in COVID-1

Author(s) -

Selçuk Görmez,

Hilal Kurtoğlu,

Erkan Ekicibaşi,

Aleks Değirmencioğlu,

Atmika Paudel,

Gökçe Akan,

Fatmahan Atalar,

Refik Erdim,

Emre Eroğlu,

Selçuk Dağdelen,

Nevin Sarıgüzel,

Ceyda Kirisoglu,

Burak Pamukçu

Publication year - 2021

Publication title -

bratislavské lekárske listy/bratislava medical journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.387

H-Index - 32

eISSN - 1336-0345

pISSN - 0006-9248

DOI - 10.4149/bll_2021_093

Subject(s) - low molecular weight heparin , medicine , propensity score matching , intensive care unit , observational study , covid-19 , thrombosis , heparin , d dimer , mechanical ventilation , retrospective cohort study , venous thrombosis , disease , infectious disease (medical specialty)

Low molecular weight heparin (LMWH) may provide beneficial effects on outcomes of COVID-19. We aimed to examine the impact of LMWH treatment on clinical outcomes (duration of hospitalization, admission to intensive care unit, the requirement for mechanical ventilation, and death) of COVID-19 patients with normal D-dimer levels at admission.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research